Background. Respiratory syncytial virus (RSV) is a leading cause of infant morbidity and mortality. A recombinant RSV fusion protein nanoparticle vaccine (RSV F vaccine) candidate for maternal immunization was tested for safety and immunogenicity in women of childbearing age.
Respiratory syncytial virus (RSV) infection is the most common cause of lower respiratory tract infection and the leading viral cause of severe lower respiratory tract disease in infants and young children worldwide, with estimated annual infection and mortality rates of 64 million and 160 000, respectively [1] . In the United States, RSV is responsible for approximately 57 000 hospitalizations of children under 5 years of age annually, the vast majority occurring in term infants less than 1 year old, and especially those under 6 months of age [2] [3] [4] . Despite the induction of postinfectious immunity, repeat infections and lifelong susceptibility is common [5] .
RSV has 2 major surface glycoproteins: the fusion (F) protein that mediates fusion of the viral envelope with host membranes, enabling the delivery of viral RNA into the host cytoplasm; and the attachment (G) protein that mediates viral attachment. The F protein is highly conserved with defined virus neutralizing sites, including the antigenic site II that is preserved in both the prefusion and postfusion forms of the protein [6] [7] [8] . Prophylactic use of monoclonal antibodies (palivizumab and motavizumab) that bind antigenic site II has been shown to reduce RSV infant hospitalizations in 5 randomized clinical trials [9] [10] [11] . Thus, induction of immunity to the RSV F protein and in particular to antigenic site II, may de-risk the development of a novel RSV vaccine. A prior Phase 1 study in healthy adults showed the RSV recombinant F nanoparticle vaccine (termed RSV F vaccine) was well tolerated and induced robust immunogenicity [12] . The current study describes the safety and immunogenicity of 9 formulations, including single-and 2-dose regimens, of a candidate RSV F vaccine in women of childbearing age, toward use in maternal immunization for protection of infants against RSV disease.
METHODS

Study Conduct
This Phase 2 randomized, observer-blind, placebo-controlled study was conducted at 4 sites in the United States (San Antonio, Texas; Anaheim, California; Mt. Pleasant, South Carolina; Rockville, Maryland) and in accordance with the International Conference on Harmonization Good Clinical Practice and the Declaration of Helsinki. The protocol and informed consent were reviewed and approved by Western Institutional Review Board, and all subjects provided written informed consent. The trial was registered with ClinicalTrials.gov (NCT01704365).
Healthy, 18-35-year-old nonpregnant and nonlactating women were randomize to 1 of 9 active groups (30 subjects/ group) or the placebo group (60 subjects), with equal distribution of each age stratum (18-<26 and 26-35) into each group. The study was designed to assess the immunogenicity and safety of 9 different vaccine formulations containing 60 or 90 µg dosages of the RSV F vaccine, with or without 1.2 mg aluminum phosphate (Al), as a 1-or 2-injection regimen, compared with both placebo and the Phase 1 vaccine formulation (Supplementary Table 1 ).
Test Articles
The RSV F protein in the postfusion confirmation was prepared as previously described [13] . The unadjuvanted, 60 or 90 µg RSV F vaccine was formulated in 25 mM phosphate buffer, pH 6.2, with 0.15 M NaCl, 1% histidine, and 0.01% polysorbate (PS)-80. The adjuvanted RSV F vaccines (same dosages) were preformulated in 12.5 mM phosphate buffer, pH 6.2, with 0.15 M NaCl, 0.5% histidine, 0.005% PS-80, and 2.4 mg/mL aluminum phosphate (AdjuPhos, Brenntag Biosector, Frederikssund, Denmark). The Phase 1 model (comparator) treatment [12] , consisting of 60 µg RSV F vaccine in 25 mM phosphate buffer, pH 7.2, with 0.5 M NaCl and 0.01% PS-80, mixed with the aluminum adjuvant (2.4 mg/mL) provided in 0.15 M NaCl without buffer prior to injection, was also included. The placebo consisted of isotonic saline. Vaccinations were administered as 0.5 mL intramuscular injections into the deltoid, on day 0 and day 28 (±2 days) in the 2-dose regimens in opposite arms. Single-dose regimens with active vaccine given on day 0 included a placebo dose on day 28 to preserve the blind.
Safety Assessments
Vaccinees were monitored for approximately 30 minutes postinjection for observation of immediate local or systemic reactions. Diaries were given to all subjects for capture of adverse events (AEs), including solicited local ( pain, bruising, redness, and swelling at the injection site) and systemic reactions (oral temperature, headache, myalgia, arthralgia, fatigue, chills, vomiting, nausea, and diarrhea) occurring for the first 7 days after each vaccination; unsolicited events, concomitant medications, physicians visits, and hospitalizations were collected through day 182.
Safety assessments were performed at day 0 and postvaccination on days 7, 28, 35, 56, 84, 112, and 182, and included vital sign collection; review of all solicited and unsolicited, local, and systemic AEs; review of concomitant medications and procedures; urine pregnancy testing (days 0 and 28); and clinical laboratory safety testing of serum chemistry analytes (alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase, creatinine, and blood urea nitrogen), and hematology parameters (complete blood count with hemoglobin, hematocrit, red blood cell, platelet, and white blood cell differential; prior to vaccination on days 0 and 28; and days 7 and 35). The 182-day follow-up period spanned an RSV season (December-March 2013).
Immunogenicity Evaluations
Anti-F immunoglobulin G (IgG), palivizumab-competing antibody (PCA), and antigen site II peptide-specific IgG enzymelinked immunosorbent assays (ELISAs) were performed as previously described [12] on serum samples collected on days 0 (baseline), 7, 28, 56, 84, and 112. Geometric mean concentrations of PCA were expressed in µg/mL. Serum-neutralizing antibodies against the RSV/A Tracy (A2-like virus) and RSV/B (18 537) strains were measured using a qualified microneutralization (MN) assay as previously described [14] . Anti-F IgG antibodies were used to evaluate whether aluminum adjuvant effect could be demonstrated, if a 2-dose immunization regimen was superior to a 1-dose, and if increasing the RSV F dose (from 60 to 90 µg) resulted in enhanced immune responses.
RSV-Western Blot
The RSV-Western blot (WB) assay was used to detect new RSV infections via antibody binding to internal and surface proteins of RSV as previously described [15] . Electrophoretically separated and membrane-bound antigens of sucrose purified RSV/A/ Bernett (GA1 genotype) were probed with subject serum samples collected for immunogenicity assessments.
Statistical Analyses
Immunology analyses were conducted using the per-protocol population, defined as all subjects who received all assigned doses of the randomized treatment on days 0 and 28 and provided serology results at days 0, 28, and 56. Differences between the adjuvanted and unadjuvanted, dose regimens, and 60 or 90 µg antigen doses were assessed by a t test on the log-transformed serum anti-F IgG ELISA unit (EU) values. Both adjuvanted 60 and 90 µg, and unadjuvanted 60 and 90 µg vaccine groups were pooled for the analysis after testing for homogeneity of variance for each group. Absence of homogeneity indicated pooling was inappropriate and no definitive conclusions can be drawn from the data. In addition, analysis of the geometric mean titer ratio of adjuvant to unadjuvanted (GMR Adj/Unadj ) vaccine groups was performed using analysis of covariance (ANCOVA), with baseline EUs as covariate. T test from the AN-COVA was used to compare the pooled adjuvanted groups with the pooled unadjuvanted groups. All statistical analyses were 2-tailed and assessed at the 5% significance level using SAS statistical software (version 9.2).
The safety population, defined as all subjects who received any test article dose, was used for all safety analyses. The primary variable for evaluation of the safety profile was the number and percentage (with 95% confidence interval [CI]) of subjects with solicited and unsolicited AEs recorded postvaccination. No statistical contrasts were performed across groups.
RESULTS
Demographics and Subject Disposition
All subjects in the study were females between the ages of 18-35 years, with mean group ages of 25.6-26.7 years and a similar distribution in the 18-25-and 26-35-year-age strata across the 10 treatment groups. Thirty-eight percent to 60% of subjects lived in a household with at least 1 school-aged child. The majority of subjects were white (57%-90%) or black (7%-28%), while 20%-55% were Hispanic or Latino. See Figure 1 for subject disposition.
Safety
Overall, all vaccines were well tolerated. The most commonly reported AEs were injection-site reactions, mainly mild to moderate pain, reported by 63%-83% of aluminum-adjuvanted vaccine recipients and 27%-48% of unadjuvanted vaccine recipients, compared with 20% of placebo recipients ( Figure 2A ). No increase in local reactogenicity was noted in active groups following second doses of active vaccine when AE incidences were examined by dose (data not shown), nor did antigen dose appear to have a substantial effect (compare profiles in 60 vs 90 µg recipients of similar dose schedules/formulations). The most frequently reported solicited systemic events in active vaccinees were headache (20%-43%), fatigue (13%-53%), muscle pain (3%-40%), nausea (3%-27%), and chills (0%-20%); at least 2-3 active vaccine groups were within the range of incidences noted in placebo recipients ( Figure 2B ). There were no deaths in the study. Three SAEs, 1 in an active vaccine recipient (acute appendicitis in the 2-doses/90 µg+Al group, 20 days following the first dose), and 2 in placebo recipients (1 acute cholecystitis and 1 pneumothorax) were considered unrelated to the study treatments. No clinical laboratory trends distinguished actively treated subjects from placebo recipients.
Immunogenicity
All RSV F vaccine formulations, with and without aluminum adjuvant, in either immunization regimen were immunogenic (Table 1) . Anti-F IgG antibody responses were detectable as early as 7 days postvaccination, reached maximal levels 28 days after the first or second vaccination, and persisted through 112 days after the first vaccination. Levels were significantly higher than placebo at all the postvaccination time points. At baseline, anti-F IgG values were >400, the lower limit of quantitation (LLoQ) of the assay, indicating that all subjects had prior exposure to RSV. While values peaked on day 28 in the single-dose groups (with and without aluminum adjuvantation), there was a further increase on day 56 in those groups administered a second dose of the adjuvanted vaccine.
Impact of Adjuvant, Antigen Dose, and Dose Schedule on Immunogenicity
Based on the anti-RSV F IgG levels, aluminum adjuvantation produced a positive effect on the immune response and resulted in 1.4-fold higher antibody levels on day 28 and 1.7-fold higher antibody levels on day 56 compared with unadjuvanted vaccine recipients (P < .05, Supplementary Table 2A) . The day-56 data Incidence rates of solicited local (A) and systemic (B) AEs at greatest severity after either dose. Solicited AEs were collected by diary through the first 7 days following any vaccination. The total incidence for each event is the sum of all severities (mild, moderate, severe) reported after any dose. Subjects with multiple occurrences of the same event were counted only once using the event of highest severity. (Commonly reported solicited systemic AEs are shown.). Abbreviations: AEs, adverse events; Al, aluminum phosphate. Abbreviations: Al, aluminum phosphate; Anti-F, anti-fusion protein nanoparticle; CI, confidence interval; GMC, geometric mean concentration; GMR, geometric mean titer ratio; GMT, geometric mean titer; IgG, immunoglobulin G; n, number of evaluable subjects; PCA, palivizumab-competitive antibody; Ph1, Phase 1.
indicated that 2 doses of the vaccine were better than a single dose (1.4-and 1.2-fold higher for pooled adjuvanted and unadjuvanted recipients, respectively), but this trend was only statistically significant with aluminum adjuvantation (P = .001) and not without (P = .137, Supplementary Table 2B ). The higher antigen dose (90 µg) provided a modest advantage in the resulting antibody increases, and this was most apparent with the unadjuvanted formulations.
Palivizumab-Competitive and Antigenic Site II (Peptide) ELISAs
The PCA results paralleled the anti-F IgG analysis (Table 1) . However, in contrast to anti-RSV F IgG antibodies, baseline PCA titers were at, or near, the assay LLoQ (33) in all subjects. Peak PCA responses were observed in the 90 µg/adjuvanted, 2-dose regimen at day 56 (324 µg/mL). Two-dose adjuvanted vaccine groups achieved the highest peak responses with 8.3-9.4-fold higher titers than baseline on day 56, followed by the single-dose adjuvanted vaccine groups (GMR Post/Pre : 6.9 and 7.9 on day 28). Proportions of subjects who displayed 4-fold increases in titer (seroconversion) followed the same trend, with peak seroconversion rates of 92%-100% in the 2-dose adjuvanted vaccine groups and 89%-93% in the single-dose adjuvanted vaccine groups. Antigenic site II ( peptide) IgG titers increased after the first dose with all active vaccines, and increased further after the second dose with adjuvanted vaccines, achieving peak geometric mean titers (GMTs) of 5465-7181 on day 56, corresponding to a 25.6-39.7-fold increase in titers relative to baseline (Table 1 ). In the absence of the aluminum adjuvant, titers resulting from 2-dose vaccine regimens were lower (GMT: 2563 and 2854; GMR Post/Pre : 9.7 and 11.1), with only small increases from day 28 to 56.
Concordance Between Anti-F and PCA
A post hoc concordance analysis [16] using anti-F IgG and PCA was performed using pooled adjuvant and unadjuvanted groups ( Figure 3A) . The figure illustrates that few subjects had measurable PCA titers on day 0 despite the presence of anti-F IgG. After immunization, the increases in anti-F IgG and PCA were concordant, with the closest relationship (concordance slope: 1.04 [95% CI, .85-1.27]) seen in the adjuvanted vaccines ( Figure 3B and 3C) .
RSV/A and B Microneutralization
Baseline MN titers across all treatment groups ranged from 303-460 for RSV/A and 94-328 for RSV/B (Table 2) . A prior study suggests 6 log 2 (64) and 8.0 log 2 (256) as the minimal protective MN titer against RSV/A and B, respectively [14] . Increases in RSV/A MN titers were noted in all active groups as early as 7 days postimmunization, with an observed 1.4-2.1-fold increase in GMT relative to baseline. In contrast to the anti-F IgG analysis, RSV/A MN titers peaked in all active groups on day 28, with 2.0-3.9-fold increases in GMTs. The aluminumadjuvanted vaccine groups generally achieved the highest titers (GMT range: 1113-1482) compared with the unadjuvanted Figure 3 . Anti-F IgG and palivizumab-competitive antibody concordance. Scatter plots of anti-F IgG versus palivizumab-competing antibody titers at baseline in all groups (A); postvaccination on day 28 (B) in placebo recipients (red circles), pooled adjuvanted RSV F vaccine recipients (blue triangles), and pooled unadjuvanted RSV F vaccine recipients (green squares); or pooled adjuvanted RSV F vaccine recipients only (blue squares) (C). The hatched blue line denotes the perfect concordance, while the solid red line denotes the observed concordance. Abbreviations: Anti-F, anti-fusion protein nanoparticle; ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; RSV, respiratory syncytial virus; RSV F vaccine, RSV recombinant F nanoparticle vaccine. vaccine groups (GMT range: 712-1139). RSV/A MN titers declined in all groups over the study period, including the placebo group that had an approximately 40% decline. The MN results indicated that 1 or 2 doses of the RSV F vaccine formulations, with or without aluminum and at the 60 or 90 µg dose level, were able to shift the lowest MN titer producers to become higher MN titer producers postvaccination (Figure 4 ). RSV/B MN titers increased more slowly, peaking on day 56 in all but 3 active vaccine groups (ie, the one 60 µg-dose, one 90 µg-dose, and two 60 µg-dose groups). The 1-and 2-dose adjuvanted groups behaved similarly, as peak titers ranged from 347-582 for a 2.1-3.5-fold GMT increase on day 56. For unadjuvanted groups, antigen dose appeared to contribute more to the resulting titer than the immunization regimen, as peak titers were 419 and 425 for the 90 µg dose groups, compared with 252 and 350 for the 60 µg dose groups. Although, when normalized for the baseline titer, peak GMRs were actually slightly higher in the 60 µg dose groups (1.5 and 2.2) than the 90 µg dose groups (1.3 and 1.7). At day 112, the RSV/A MN fold-rise in vaccinees declined to levels lower than baseline but higher than placebo recipients, while the RSV/B MN fold-rises were above baseline in all groups. The interpretation of these differences is confounded by the contribution and decay of naturally induced antibodies present at baseline, the variability in the individual MN values, and the onset of the RSV season where infections would be expected to induce rises in MN.
Western Blot
Given the generally high level of immune responses against RSV in RSV F vaccinees, the WB analysis was performed post hoc in a blinded fashion to compare infection rates in all active vaccinees versus placebo. Among the 269 pooled active vaccinees and 61 placebo subjects, 15% in each category had evidence of recent-past RSV infection at day 0 ( Figure 5 ). At day 56 postimmunization, 4% in each category had evidence of a new RSV infection during the day-0-day-56 period. During the RSV season (December to March), which corresponded to study days 56 to 112, only 11% (26/244) of vaccinees had evidence of new RSV infection compared to 21% (12/56) of placebo recipients.
DISCUSSION
RSV disease in newborn infants occurs despite the presence of antibody titers conferred by the transplacental antibody transfer of neutralizing antibodies to infants from mothers [17] . Although it is clear that high levels of MN antibodies are protective [18, 19] , the lack of protection seen in newborns and the lifelong recurrences of RSV infections [5, 20, 21] indicate that the robust immunity developed in response to wild-type infections is insufficient in quality and quantity to confer high levels of protection. The need for an RSV vaccine has been recognized for many decades and warrants evaluation of new approaches such as the RSV F nanoparticle vaccine. Abbreviations: Al, aluminum phosphate; CI, confidence interval; GMR, geometric mean titer ratio; GMT, geometric mean titer; MN, microneutralization; Ph1, Phase 1; n, number of evaluable subjects; RSV, respiratory syncytial virus.
Two monoclonal antibodies, palivizumab and motavizumab, which bind to antigenic site II of the F protein, have been evaluated in randomized clinical trials and shown to prevent severe RSV disease [9] [10] [11] . They have been extensively evaluated as drugs in preclinical efficacy and clinical pharmacokinetic studies that defined antibody levels associated with protection [22] . The predictive nature of the cotton rat model, elucidation of the antibody-binding site and the mechanism of action [23] , and protection using the monoclonal antibodies in clinical settings provide a roadmap for development of a novel RSV vaccine. A palivizumab concentration of >30 µg/mL was shown to decrease pulmonary RSV replication in the cotton rat model by >100-fold [22] . Using the cotton rat studies as guidance, trough levels of 40 µg/mL were achieved through dosing studies in infants and were subsequently associated with high levels of protection against severe RSV disease in randomized clinical efficacy trials [9] [10] [11] . The RSV F vaccine has also been shown to present other neutralizing epitopes, to elicit antibodies that have higher binding affinities than palivizumab and to protect against site II mutant viruses that no longer bind palivizumab [24] . The immunogenicity data in this study suggest that women immunized in the third trimester with this vaccine could confer protective levels of antibodies to their infant via placental transfer given that the immunogenicity can be reproduced in pregnant women. G, F1, nucleoprotein, phosphoprotein, and matrix protein, respectively. A "recentpast RSV infection" profile was characterized by the visualization of 2 or more of these protein bands at enrollment. An "acute RSV infection" profile was characterized by an increase in intensity or the identification of new bands that correspond to 1 or more proteins. The evaluation was a post hoc, blinded analysis. Subjects identified as having had a "recent-past RSV infection" based on day 0 serum samples were included in the analysis for an "acute RSV infection." Data shown are the percentage of subjects with a past or acute RSV infection based on the number of subjects with evaluable serum samples at each time point. There were 269, 249, and 244 evaluable subjects for the All Vaccine group, and 61, 57, and 56 evaluable subjects for the Placebo group at days 0, 56, and 112, respectively.Abbreviation: RSV, respiratory syncytial virus.
The current study expands on a Phase 1 safety and immunogenicity trial [12] , and shows that the RSV F vaccine is well tolerated and immunogenic, inducing antibodies that compete with palivizumab binding to the F protein and that have neutralizing activity against both RSV/A and B. Remarkably, although healthy adults have relatively high levels of RSV/Aand B-specific MN antibodies in their serum samples at baseline due to a lifetime of natural infections, PCA levels are very low prior to immunization. In contrast, immunity to the linear epitope is present in the general population, as indicated by the antibodies to the antigenic site II peptide, suggesting that adults are primed to this epitope in addition to the F protein itself. These antibodies are effectively boosted after a single dose of the RSV F vaccine and parallel the increase observed in PCA. Together, these observations suggest that the antigenic site II conformational epitope is not readily exposed during natural infection, consistent with the need to keep this region immunologically cryptic due to its critical role during viral fusion and pathogenesis [23] .
The intended use of the RSV F vaccine for maternal immunization follows a proven and effective paradigm for protecting infants-and in some cases, the pregnant woman-against important diseases. The prevention of neonatal tetanus, infant pertussis, and adult and infant influenza via maternal immunization has been established as a major public health success [25] [26] [27] [28] [29] and suggests that this may be a viable strategy for protection of infants against RSV disease. Active Fc-γ receptormediated transport of maternal IgG begins early in gestation, with significant levels attained by 28 weeks' gestational age [30] . Concentration of antibodies in the fetus to a level that is typically higher than that found in the mother is generally observed by 36 weeks' gestational age [31] , and has been described for a number of protein-based vaccines [32] . Thus, the transplacental transport of IgG antibodies that have PCA and MN activity as a result of maternal immunization with an RSV F vaccine has been demonstrated in guinea pigs [Glenn, in press]. The efficacy of this in protecting the infant will need to be assessed in randomized, placebo-controlled, double-blinded clinical trials.
Using the RSV-WB assay, we were also able to study whether these healthy adult women had been infected with RSV after an RSV season (between study days 56 and 112) and whether a protective vaccine effect could be observed. Consistent with other studies [33] , we observed a substantial rate of new antibody responses consistent with RSV infections in the placebo cohort and report for the first time a reduction by 50% in RSV F vaccinees based on serology. This post hoc observation is limited to infection and not disease, but is consistent with data in cotton rats [34] and humans [35] where reduction of infection in the nasal passage was observed to be a good indicator of levels of protection against disease of the lower respiratory tract. Although there is limited epidemiologic data for RSV disease in pregnant women, its presence and pathology in this population is likely [33, 36] . Protecting the mother against RSV infection would be an important benefit of maternal immunization with an RSV F vaccine.
In the current study, the different formulations of the candidate RSV recombinant F nanoparticle vaccine were well tolerated in healthy women of childbearing age, and induced immune responses that may be consistent with protection against RSV disease. The study confirmed the value of a higher antigen dose, the increased immunity with aluminum phosphate, and the potential for a single-dose vaccine. Although the major limitation of this study is that it was not performed in pregnant women, the special, vulnerable nature of this target population will require considerable generation of safety data in women of childbearing age to ensure that it is safe. During the dose-finding/dose-schedule studies, additional insights regarding immune responses and vaccine effects that will support the selection of a dose regimen for maternal immunization will be made. A single-dose regimen would be ideal for immunization of women in the third trimester of pregnancy. The use of aluminum and increased antigen dose in a single immunization should be evaluated in pregnant women to protect the newborn infant and the pregnant mother against RSV disease.
Supplementary Data
Supplementary materials are available at http://jid.oxfordjournals.org. Consisting of data provided by the author to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the author, so questions or comments should be addressed to the author.
Notes
Financial support. This work was supported in part by PATH (formerly Program for Appropriate Technology in Health), Seattle, Washington.
Potential conflicts of interest. G. M. G., L. F. F., D. N. T., G. S., E. K., H. L., D. F., D. J., and S. P. H. are salaried employees of Novavax and hold stock options. P. A. P. has served as a consultant and has received financial support for laboratory procedures from Novavax. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
